Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE).

Timeline

Start

2025-08-25

Primary completion

2027-06

Completion

2028-12

Drugs

Indications